Article

Lipid lowering effects of Momordica charantia (Bitter Melon) in HIV-1-protease inhibitor-treated human hepatoma cells, HepG2

University of Hawaiʻi at Mānoa, Honolulu, Hawaii, United States
British Journal of Pharmacology (Impact Factor: 4.84). 09/2006; 148(8):1156-64. DOI: 10.1038/sj.bjp.0706821
Source: PubMed

ABSTRACT

1. Hyperlipidemic effects of HIV-1-protease inhibitors (PI) are associated with increased hepatic production of triglyceride (TG)-rich lipoproteins, rather than lipoprotein clearance. PI are known to increase apolipoprotein B (apoB) secretion, apoC-III mRNA expression and decrease apoA-1 secretion. Nutritional therapy remains an important strategy to manage PI-associated hyperlipidemia. 2. This study investigated the in vitro efficacy of Asian vegetable, Momordica charantia or bitter melon (BM) to ameliorate PI-associated apoB and lipid abnormalities in HepG2 cells. 3. Our study demonstrates that bitter melon juice (BMJ) significantly reduced apoB secretion and apoC-III mRNA expression and normalized apoA-I expression in PI-treated HepG2 cells. BMJ also significantly reduced cellular TG and microsomal TG transfer protein, suggesting that lipid bioavailability and lipidation of apoB assembly may play a role in decreased apoB secretion. 4. Identifying molecular targets of BM may offer alternative dietary strategies to decrease PI-associated hyperlipidemia and improve quality of life among HIV-1-infected patients.

Download full-text

Full-text

Available from: Vivek Nerurkar, Sep 01, 2015
    • "In recent years, a number of chemical component that possess medicinal attributes have been isolated from bitter gourd, such as c-momorcharin which inactivates ribosome function (Feng et al., 1990; Leung et al., 1997) and stimulates MAP30 (Momordica anti-HIV protein) production which in turn, simultaneously suppresses HIV (human immunodeficiency virus) activity (Lee-Huang et al., 1990, 1995). Interestingly, momordicoside A and B present in bitter gourd inhibit tumor growth (Okabe et al., 1980) and several bitter gourd phytochemicals have in vitro antiviral activity against viruses including Epstein-Barr, herpes and HIV viruses (Lee-Huang et al., 1990; Nerurkar et al., 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Plant Momordica charantia Linn., known as bitter gourd, belongs to family Cucurbitaceae. It is cultivated throughout India, Malaya, China, Tropical Africa and America. Earlier claims showed that its bitter fruits have carminative, aphrodisiac and anthelmintic properties are used in syphilis, rheumatism, troubles of spleen and ophthalmia. It is also useful in piles, leprosy, jaundice and used as a vermifuge. Literature review reveals that the fruit of plant contains moisture (83.2%), proteins (2.9%), fat (1.0%), carbon (9.8%), fibers (1.7%), mineral matters (1.4%), calcium, phosphorus, iron, carotene, thiamine, nicotinic acid, riboflavin, ascorbic acid (88 mg/100 g), copper and potassium. Charantin, β-sitosterol-glucoside, stigmast-5, 25-dien-3 β-O-glucoside, stigmast-7, 25-dien-3 β-ol and stigmast-7, 22, 25-trien-3 β-ol are isolated from the fruit. Many pharmacological properties of M. charantia have been reported, including antioxidant, adipogenesis-reducing, antilipolytic, hypoglycemic, antidiabetic, anticancer, antifertility, anthelmintic, antimicrobial, antiviral and hepatoprotective activity. The present review highlights the salient pharmacological uses of Momordica charantia.
    No preview · Article · May 2015
  • Source
    • "Bitter melon (Momordica charantia) is widely cultivated in Asia, Africa, and South America, and extensively used in folk medicines as a remedy for diabetes, specifically in South East Asia. Animal studies have employed either fresh bitter melon extract (BME) or crude organic fractions to evaluate its beneficial effects on glucose metabolism and on plasma and hepatic lipids [4], [5]. We have previously shown that BME (without seeds) treatment of human cancer cells induced cell cycle arrest by altering critical signaling molecules and impairing cell growth [6], [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Head and neck squamous cell carcinoma (HNSCC) remains difficult to treat, and despite of advances in treatment, the overall survival rate has only modestly improved over the past several years. Thus, there is an urgent need for additional therapeutic modalities. We hypothesized that treatment of HNSCC cells with a dietary product such as bitter melon extract (BME) modulates multiple signaling pathways and regresses HNSCC tumor growth in a preclinical model. We observed a reduced cell proliferation in HNSCC cell lines. The mechanistic studies reveal that treatment of BME in HNSCC cells inhibited c-Met signaling pathway. We also observed that BME treatment in HNSCC reduced phosphoStat3, c-myc and Mcl-1 expression, downstream signaling molecules of c-Met. Furthermore, BME treatment in HNSCC cells modulated the expression of key cell cycle progression molecules leading to halted cell growth. Finally, BME feeding in mice bearing HNSCC xenograft tumor resulted in an inhibition of tumor growth and c-Met expression. Together, our results suggested that BME treatment in HNSCC cells modulates multiple signaling pathways and may have therapeutic potential for treating HNSCC.
    Full-text · Article · Oct 2013 · PLoS ONE
  • Source
    • "In recent years, a number of chemical components that possess medicinal attributes have been isolated from bitter gourd, such as c-momorcharin, which inactivates ribosome function (Feng et al. 1990; Leung et al. 1997) and stimulates MAP30 (Momordica anti-HIV protein) production, which, in turn, simultaneously suppresses HIV (human immunodeficiency virus) activity (Lee et al. 1990, 1995). Interestingly, momordicoside A and B present in bitter gourd inhibit tumor growth (Okabe et al. 1980), and several bitter gourd phytochemicals have in vitro antiviral activity against viruses including Epstein-Barr, herpes, and HIV viruses (Takemoto 1983; Lee et al. 1990; Nerurkar et al. 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: This chapter contains sections titled: Introduction Botany Horticulture Breeding Conclusions Literature Cited
    Preview · Article · Jul 2010
Show more